Yu Bai

Yu Bai started their work experience in 2007 as an Associate Scientist at Hutchison MediPharma, where they established a new platform for drug discovery and performed various assays to study the mode of action (MOA) of candidate hits. They were responsible for cell culture, PD sample analysis, and conducting cell proliferation/apoptosis assays. In 2008, Yu Bai joined Astrazeneca as an Associate Scientist, supporting Olaparib in vitro biomarker studies and MOA studies for translational science projects. They also developed and validated different assays for the project team. In 2010, they were promoted to Senior Associate Scientist, where they continued to serve as an in vitro lead for two oncology projects. They established EGFR Tki resistant cell lines and delivered key documents for milestone transitions and IND filings. In 2013, Yu Bai became a Scientist at Astrazeneca, where they continued to serve as an in vitro lead for oncology projects, collaborating with doctors to explore the MOA of potential drug resistance. In 2017, they joined Dizal Pharma as a Project Leader, responsible for assembling project teams, creating work plans, organizing project team meetings, and presenting project progress to review meetings.

Yu Bai's education history begins in 1999 when they attended Lanzhou University and completed a Bachelor's degree in Biological Technology in 2003. They then pursued further education at Lanzhou University and obtained a Master's degree in Developmental Biology from 2003 to 2006. After that, they attended the University of Chinese Academy of Sciences and completed a Master's degree in Agricultural Biology from 2004 to 2006. Most recently, from 2017 to 2020, Yu Bai attended Peking University and obtained a Doctorate in Biomedical Engineering.